Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.
Riddle
Matthew C
MC
Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA.
Drucker
Daniel J
DJ
D000682:Amyloid / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology / Q000627:therapeutic use*; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide; D018027:Receptors, Glucagon / Q000627:therapeutic use*
D000682:Amyloid; D001786:Blood Glucose; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D018027:Receptors, Glucagon; D052216:Glucagon-Like Peptide 1